Compare Anheuser-Busch Inbev SA (BUD) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Anheuser-Busch Inbev SA vs 10X Genomics Inc — how do they compare? Anheuser-Busch Inbev SA trades at $79.6 (market cap $159.01B), while 10X Genomics Inc trades at $59 (market cap $7.61B). The key difference: Anheuser-Busch Inbev SA is far larger — about 20.9× 10X Genomics Inc's market cap, and Anheuser-Busch Inbev SA pays a 1.67% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| BUD | TXG | |
|---|---|---|
Market Cap | $159.01B | $7.61B |
Sector | Consumer Staples | Health |
52-Week High | $86.48 | $58.57 |
52-Week Low | $57.93 | $11.34 |
Enterprise Value | $223.42B | $7.14B |
Dividend Yield | 1.67% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
